Ordination Dr. Peter Würtz
- Address
- Uferstraße 4, 4710 Grieskirchen, Austria
Ordination Dr. Peter Würtz - Respiratory Medicine Research
Ordination Dr. Peter Würtz is a clinical research center specializing in respiratory medicine with a particular focus on chronic obstructive pulmonary disease (COPD) management and treatment. The center demonstrates expertise in evaluating novel therapeutic approaches for patients with moderate to very severe COPD, particularly those experiencing frequent disease exacerbations.
- Advanced COPD management and exacerbation prevention strategies
- Biologic therapies targeting eosinophilic inflammation in respiratory disease
- Clinical trials for patients with elevated peripheral blood eosinophils
The center's research portfolio emphasizes the evaluation of benralizumab and other targeted biological agents designed to reduce exacerbation frequency in COPD patients. With dedicated focus on patients presenting with elevated eosinophil levels, the center contributes valuable data on precision medicine approaches in respiratory disease management, helping to identify optimal treatment strategies for specific COPD phenotypes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ordination Dr. Peter Würtz
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Benralizumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease with Frequent Exacerbations | AstraZeneca AB | Phase III | Not Recruiting | Nov 2019 | Jul 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tanimilast | 2 | Unknown | 2021-06-16 | 2021-06-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.